Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib plus capecitabine versus capecitabine for advanced metastatic colorectal cancer
ChiCTR1800014504Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Rivoceranib and capecitabine in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Affiliated Hospital of North Sichuan Medical College. Primary endpoint: Progression-free survival. Planned start Feb 2018; status: not yet recruiting.
02
Drugs
Rivoceranibcapecitabine
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on ChiCTR1800014504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014504.